IPO in HK
Investigation Report on China Budesonide Market, 2010-2019 View full size

Investigation Report on China Budesonide Market, 2010-2019

With the climatic and environmental changes, seasonal asthma has become the main reason for respiratory ailments. According to an epidemiological survey, the incidence of…

More details

$ 2,000

Add to cart

English
Chinese
Description

With the climatic and environmental changes, seasonal asthma has become the main reason for respiratory ailments. According to an epidemiological survey, the incidence of respiratory ailments is 16% of the incidence of all diseases. About 280 million people in the world suffer from different degrees of seasonal asthma, more so in industrialized countries and regions where tobacco consumption is high. 5% of adults and 20% of children there have been attacked by this disease and many of them come down with bronchial asthma induced by chronic cough.
Nearly 300 million people in China contract respiratory ailments, among which over 50 million suffer from cough with an annual growth rate of 4% and 15-20 million asthma.
Budesonide, an adrenocortical hormone, was developed by Astrazeneca in the 1990s. It is mainly used for the treatment of non-glucocorticoid dependent or glucocorticoid-dependent bronchial asthma and chronic obstructive pulmonary disease (COPD). In Jun. 1997, budesonide aerosol got FDA’s approval. In recent years, with the steady growth of global demand, budesonide has occupied an important position in the TOP10 respiratory drugs.
In 1994, China approved the import of budesonide for clinical purposes. After being marketed by Astra (Wuxi) in China in 1995, budesonide develops fast with annual sales rising from CNY 60 million in 2005 to CNY 595 million in 2014 and CAGR reaching up to 29% during the period of 2005-2014. Budesonide enjoys a vast demand in China. Currently, budesonide in the Chinese market mainly come from the following companies: Lunan Better Pharmaceutical Co., Ltd, Orion Corporation (Finland), WELLCOME AUSTRALIA LTD.(AU), SYNMOSA BIOPHARMA CORPORATION (TW) and Astra AB (Sweden). While they all take up certain shares in the market, WELLCOME AUSTRALIA LTD.(AU) has the largest market share of 88% with sales value reaching up to CNY 524 million in 2014.
The market size of budesonide in China is expected to keep growing in the next few years.

Readers can get at least the following information from this report:
-market size of budesonide in China
-market share of manufacturers of budesonide in China
-price of budesonide in Chinese market
-major manufacturers of budesonide in Chinese market
-market outlook of budesonide in China

The author suggests the following groups of people purchase this report:
-manufacturers of cortin drugs
-investors/ research institutions interested in Chinese medicine market
-any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1 Related Concepts of Budesonide
1.1 Indication
1.2 Sales Status in Global Market

2 Market Profile of Budesonide in China
2.1 Patent and Approval Status of Budesonide in China
2.2 Major Manufacturers
2.3 Market Size

3 Survey on Sales Status of Budesonide in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions

4 Survey on Market Share of Major Manufacturers of Budesonide in China, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 Survey on Dosage Forms of Budesonide in China, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume

6 Reference Price of Budesonide in Chinese Hospitals in 2014
6.1 SYNMOSA BIOPHARMA CORPORATION (TW) (Trade Name: Rhinocort)
6.2 WELLCOME AUSTRALIA LTD.(AU)
6.2 WELLCOME AUSTRALIA LTD.(AU)
6.3 Shanghai Sine Pharmaceutical Co Ltd (Trade Name: Bao Yi Su)
6.4 Orion Corporation (Finland) (Trade Name: Antrex)
6.5 Astra AB (Sweden) (Trade Name: Pulmicort)
6.6 Lunan Better Pharmaceutical Co., Ltd (Trade Name: Ji Shu)

7 Major Manufacturers of Budesonide in Chinese Market, 2010-2014
7.1 Shanghai Sine Pharmaceutical Co Ltd
7.2 Lunan Better Pharmaceutical Co., Ltd
7.3 Astra AB (Sweden)
7.4 WELLCOME AUSTRALIA LTD
7.4 WELLCOME AUSTRALIA LTD
7.5 SYNMOSA BIOPHARMA CORPORATION
7.5 SYNMOSA BIOPHARMA CORPORATION

8 Market Outlook of Budesonide in China, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape

Selected Charts

Chart Patent Status of Budesonide in China
Chart Approval Information of Budesonide in China
Chart Sales Status of Budesonide in China
Chart Sales Value of Budesonide in China, 2010-2014
Chart Sales Value of Budesonide in Some Regions in China, 2010-2014
Chart Sales Volume of Budesonide in China, 2010-2014
Chart Market Share of TOP4 Manufacturers of Budesonide for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Budesonide Made by WELLCOME AUSTRALIA LTD.(AU) in China, 2010-2014
Chart Sales Value and Market Share of Budesonide Made by Astra (Sweden) in China, 2010-2014
Chart Sales Value and Market Share of Budesonide Made by Lunan Better in China, 2010-2014
Chart Sales Value and Market Share of Budesonide Made by SYNMOSA(TW) in China, 2010-2014
Chart Sales Value and Market Share of Budesonide Nasal Spray in China, 2010-2014
Chart Sales Value and Market Share of Budesonide Aerosol in China, 2010-2014
Chart Price of Budesonide Made by SYNMOSA BIOPHARMA CORPORATION (TW) in Some Chinese Cities in 2014
Chart Price of Budesonide Made by WELLCOME AUSTRALIA LTD.(AU) in Some Chinese Cities in 2014
Chart Price of Budesonide Made by Sine in Some Chinese Cities in 2014
Chart Price of Budesonide Made by Orion Corporation (Finland) in Some Chinese Cities in 2014
Chart Price of Budesonide Made by Astra AB (Sweden) in Some Chinese Cities in 2014
Chart Price of Budesonide Made by Lunan Better Pharmaceutical Co., Ltd in Some Chinese Cities in 2014


  • Charts: 30
  • Pages: 30
  • Published Date: 2015/6/11
  • Geography Coverd: China
  • Publisher: China Research & Intelligence